Exploring Value-Based Contracting In Rare Diseases

Q&A with Katie Necas

How are payers and manufacturers navigating the complexities of value-based contracts for costly rare disease treatments? The lack of publicly available data makes understanding these crucial agreements difficult. This gap inspired Katie Necas, PharmD, MBA, Health Outcomes & Market Access Fellow, and her colleagues to investigate. Their research surveyed payers to uncover the realities of value-based contracting in the rare disease market, exploring everything from negotiation frequency and contract execution to the types of outcomes measured. The study also probed the current and potential utilization of artificial intelligence in structuring and managing these contracts. What did they discover about payer engagement and the actual impact of AI?

Read the full article to explore Katie Necas's detailed findings and perspective on the future of value-based care in rare diseases.